Still, the rate and extent of weight loss can lead to aesthetic concerns such as loose skin, deflated fat pockets, and uneven body contours
The pharmacokinetic rationale Semaglutide has a half-life of approximately 7 days, which is what allows for once-weekly dosing
We dont rely on BMI alone
Successful examples include semaglutide (168h), an oral octreotide formulation (restricted maintenance indication), and emerging candidates such as I-338 insulin (60h), which used sodium caprate (C10) in Novo Nordisks Phase II, trials ( 7.1 Application to FDA-approved and emerging peptides Table 2 applies this framework to representative FDA-approved peptides and emerging candidates, demonstrating how few molecules meet the criteria for oral feasibility and why the historical record of failure is the expected outcome rather than a surprising result
That one fact changes the entire conversation about GLP-1 pricing - because it means the $900/month drug at the pharmacy and the $147.90/month option from a physician-prescribed telehealth program contain the same molecule
